イリノイ州における非ホジキンリンパ腫の臨床試験
イリノイ州内の拠点で、非ホジキンリンパ腫に関する20件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- The University of Chicago Medical Center (UCMC), Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/22更新 · NCT02693535Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06526793Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Cancer Care Specialists of Central Illinois, Swansea
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06528301Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Robert H Lurie Cancer Center, Chicago
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/05更新 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northwestern, Chicago
- University of Chicago, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Robert H Lurie Cancer Center, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- University of Illinois at Chicago, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05077527A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Northwestern Memorial Hospital, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Chicago, Zion
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06915246Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- 他45件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Northwestern University, Chicago
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Northwestern University, Chicago
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。